💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring.

ja.ma/4hVydhi

Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and disease control, with no muscle-invasive or metastatic progression during follow-up.

ja.ma/4j8TEO5

Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up.

ja.ma/479i4jj

Among patients with #HepatocellularCarcinoma beyond the Milan criteria who underwent #LiverTransplant, an immune checkpoint inhibitor–based pretransplant strategy was associated with better survival and lower recurrence vs therapy without immune checkpoint inhibitors. ja.ma/4hFlgbb

Among patients with nonmetastatic #HeadNeckCancer receiving radiation therapy, financial toxicity was associated with worse quality of life and substantial out-of-pocket expenses. ja.ma/4dzMI8Z

This review examines ovarian metastases from colorectral cancer and the potential role of surgical resection of metastatic disease. ja.ma/4iKDA4S

Among adults in China and the UK, modifiable lifestyle factors and health conditions accounted for most of the male-female #Cancer incidence gap in China but only a smaller fraction in the UK. ja.ma/4ygALxm

Writing in JAMA Oncology, YSM researchers report that prostate-specific membrane antigen positron emission tomography (PSMA-PET) #imaging could shift #prostate #cancer treatment patterns by detecting previously hidden metastases. @jamaoncology.com Learn more: medicine.yale.edu/publication-...

Prebiopsy #MRI use before #ProstateCancer biopsy increased in the US from 2017 to 2026, reaching 64.1% of biopsy-naive patients, but uptake remained incomplete. ja.ma/4gPW16U

Editorial: In HPV 16–positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus pembrolizumab demonstrated activity in immune checkpoint inhibitor–naive disease but not after prior immune checkpoint inhibitor exposure. ja.ma/4xW1IWP

Meta-analysis: In #HeadAndNeckCancer with programmed cell death 1 ligand 1 combined positive score <1, #ImmuneCheckpointInhibitors were likely associated with reduced survival, including significantly reduced overall survival in recurrent or metastatic disease. ja.ma/46uMnAC

In #HPV16-positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus #Pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. ja.ma/4xVtvql

In persistent, recurrent, or metastatic #CervicalCancer, first-line #Pembrolizumab plus chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years, with no new safety signals observed. ja.ma/3UHjheC

A 76-year-old man presented to the emergency department with 5 days of worsening dyspnea at rest, lower extremity edema, fatigue, confusion, and poor oral intake. What is your diagnosis? ja.ma/4cvl6kY

Among children with relapsed or refractory #BCellAcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with high rates of minimal residual disease–negative remission and durable event-free survival. ja.ma/4hc7VYK

Among patients with #ERBB2-positive #BreastCancer, neoadjuvant anbenitamab plus HB1801 was associated with a higher total pathologic complete response rate vs trastuzumab, pertuzumab, and docetaxel, with similar grade 3 or 4 toxic effects.

ja.ma/46FBax8

💬 Editorial: In pediatric #AcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with durable remission despite limited persistence, challenging the view that prolonged CAR T-cell surveillance is always required. ja.ma/464VxDP

📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #Cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. ja.ma/3SPjlZi

📑 This JAMA Oncology review discusses #Chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage #BreastCancer. ja.ma/4x96mzy

In #CancerCare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs.

ja.ma/4ig46mA